3种用药方案治疗原发性高血压的最小成本分析

Cost-minimization Analysis of Three Pharmacotherapeutic Schemes for Hypertension

目的:评价3种用药方案治疗原发性高血压的经济学效果。方法:将156例轻、中度高血压患者随机分成A、B、C组,分别给予卡托普利+尼群地平、依那普利+氨氯地平、培哚普利+吲达帕胺治疗12周,观察疗效,并进行最小成本分析。结果:A、B、C组总有效率分别为88.24%、90.91%、92.00%,无显著性差异(P>0.05);药品成本分别为5.21、293.16、430.08元,有显著性差异(P<0.05)。结论:A组方案较经济。

OBJECTIVE： To evaluate the economic benefits of the three therapeutic regimens for hypertension. METHODS： A total of 156 patients with hypertension were randomly assigned to receive captopril plus nitrendipine （Group A）, enalapril plus amlodipine （Group B） or perindopril plus indapamide （Group C） for 12 weeks. The efficacy of the 3 groups was monitored and cost- effectiveness analysis was evaluated. RESULTS： The total effective rates of A, B and C groups were 88.24%, 90.91% and 92.00%, showing no significant differences among groups （P〉0.05） . The costs of the 3 groups were 5.21, 293.16 and 430.08yuan, respectively, showing significant differences among groups （P〈0.05） . CONCLUSION： Pharmacoeconomically, Group A （captopril plus nitrendipine） is preferable for hypertension among the 3 groups.